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Abstract Mutations of the Caenorhabditis elegans dystrophin/
utrophin-like dys-1 gene lead to hyperactivity and hypercontrac-
tion of the animals. In addition dys-1 mutants are hypersensitive
to acetylcholine and acetylcholinesterase inhibitors. We investi-
gated this phenotype further by assaying acetylcholinesterase
activity. Total extracts from three different dys-1 alleles showed
significantly less acetylcholinesterase-specific activity than wild-
type controls. In addition, double mutants carrying a mutation in
the dys-1 gene plus a mutation in either of the two major
acetylcholinesterase genes (ace-1 and ace-2) display locomotor
defects consistent with a strong reduction of acetylcholines-
terases, whereas none of the single mutants does. Therefore, in
C. elegans, disruption of the dystrophin/utrophin-like dys-1 gene
affects acetylcholinesterase activity.
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1. Introduction
Duchenne and Becker muscular dystrophies are allelic
forms of progressive myopathies caused by the disruption of
the dystrophin gene. This gene encodes a 3685 amino acid
protein found in skeletal and cardiac muscles and in the nerv-
ous system [1,2]. The function of the dystrophin protein is not
clearly established yet. It has been proposed that dystrophin is
a structural protein whose function is to increase membrane
stability during repeated cycles of muscular contraction [1,3].
The physiological function of dystrophin overlaps with that of
utrophin, a protein very similar to dystrophin and expressed
in most cell types [4]. Dystrophin is present under the sarco-
lemma of skeletal muscles, where it binds cortical actin via its
N-terminal region. Through its C-terminal region, dystrophin
binds to a complex of membrane proteins termed the dystro-
phin-associated proteins (reviewed in [5]).
The genome of Caenorhabditis elegans contains a dystro-
phin/utrophin homologue named dys-1. We previously re-
ported that loss-of-function mutations of the dys-1 gene lead
to a complex phenotype including hyperactivity, hypercon-
traction, and hypersensitivity to acetylcholine and to the ace-
tylcholinesterase inhibitor aldicarb [6]. The dys-1 gene was
shown to be expressed and required in muscle tissue [6] where
its absence may result in increased muscle excitability.
C. elegans acetylcholinesterases are encoded by at least four
genes di¡ering in their substrate and inhibitor speci¢cities (re-
viewed in [7,8]). Most of acetylcholinesterase activity is con-
tributed by the genes ace-1 and ace-2, while ace-3 and ace-4
play only a minor role. Work performed on both C. elegans
and the closely related species Steinernema carpocapsae sug-
gests that ace-1 generates a tetrameric form similar to the
mammalian amphiphilic G4 form, and ace-2 generates a gly-
colipid-anchored dimer [7,9]. The genetic tractability of
C. elegans has permitted the isolation of mutants of ace-1,
ace-2 and ace-3 [10^12]. None of these mutants displays a
major developmental or behavioral phenotype, indicating
that the worm is not dramatically a¡ected by the loss of
one of these genes. However, ace-1 ace-2 double mutants,
lacking approximately 90% of acetylcholinesterase activity,
display severely uncoordinated locomotion [11]. In contrast,
ace-1 ace-3 and ace-2 ace-3 double mutants appear normal.
The triple mutant ace-1 ace-2 ace-3 is paralyzed and devel-
opmentally arrested, dying at the hatching stage [12]. Genetic
mosaic analysis suggests that ace-1 activity is required in the
muscles of the animal, presumably at the neuromuscular junc-
tion [12,13].
C. elegans animals lacking the functional dystrophin homo-
logue dys-1 do not display any obvious muscular degeneration
phenotype, but are hyperactive and hypercontracted. The
ability of the human dystrophin cDNA to partly suppress
this phenotype indicates that a common function has been
conserved between the two proteins [6]. Moreover, the pres-
ence of several known partners of dystrophin in the C. elegans
genome further suggests that an ancestral function of dystro-
phin has been maintained through evolution. Our current
work with C. elegans dystrophin aims at determining both
the nature of this ancestral function and the common denom-
inator that could lead to phenotypes as di¡erent in appear-
ance in mammals (muscle degeneration) and nematodes (hy-
peractivity and hypercontraction).
In this study, we investigated whether the phenotypes ob-
served in C. elegans dys-1 mutants could be explained by a
decrease in acetylcholinesterase activity. We report that worm
extracts obtained from three di¡erent dys-1 alleles show a
signi¢cant reduction of total acetylcholinesterase activity,
compared to wild-type. This indicates that, in C. elegans,
the absence of dystrophin a¡ects acetylcholinesterases.
2. Materials and methods
2.1. Animal strains
Strains used in this study were obtained from the Caenorhabditis
Genetic Center (CGC), Minneapolis, MN, USA. dys-1 alleles were
isolated in our laboratory. The reference N2 strain was used as a
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wild-type control. PR1000: ace-1(p1000) ; GG201: ace-1(p1000) ace-
2(g72) ; GG202: ace-2(g72). dys-1 alleles cx18, cx26 and cx35 are
described in [6]. Their molecular nature suggests that these are severe
loss-of-function or null mutations of the gene. dys-1(cx26) ace-1-
(p1000) and dys-1(cx26) ace-2(g72) double mutants were con-
structed following standard genetic techniques [14], and their genotype
was ascertained by molecular analysis.
2.2. Acetylcholinesterase (AChE) assay
AChE activity was assayed in total worm extracts by the method of
Ellman et al. [15]. Worms were extracted using silica beads in low-salt
bu¡er (10 mM Tris, pH 7.5) containing 1% Brij 97 (10-oleyl-ether,
Sigma) and antiproteolytics (aprotinin, 7.5U1033 TIU, bacitracin,
0.1 mg/ml, benzamidine, 1 mM, EDTA, 1 mM). After centrifugation
(30 min at 12 000Ug), AChE activity was determined by the spectro-
photometric method of Ellman et al. [15] using 1 mM acetylthiocho-
line as a substrate. Protein concentration was estimated with the
Bradford assay (Bio-Rad, DC Protein Assay).
3. Results and discussion
3.1. Reduced AChE activity measured in dys-1 mutants
We assayed AChE activity on worm extracts of wild-type
and dys-1 animals. ace-1, ace-2 and ace-1 ace-2 mutants were
used as internal controls. The results are presented in Fig. 1.
All three dys-1 alleles tested, cx18, cx26 and cx35, showed a
signi¢cant reduction of the AChE activity (P6 0.05), ranging
from 59% to 69% of wild-type activity. In an attempt to de-
termine which class of acetylcholinesterase was a¡ected by the
dys-1 mutations, we then assayed the AChE activity of ace-1
dys-1(cx26) and ace-2 dys-1(cx26) double mutants (Fig. 1).
The double mutants showed a reduced activity compared to
ace-1 and ace-2 single mutants, albeit non-cumulative.
We previously showed that dys-1 phenotypes are probably
due to a lack of dys-1 expression in muscles, since dys-1 is
detected only in muscles, and dys-1 animals can be rescued
when this gene is driven by a muscle-speci¢c promoter [6].
This leads to two major (and non-exclusive) hypotheses for
the interpretation of the phenotype: either an increase of
muscle excitability or a decrease of acetylcholinesterase activ-
ity. In this study, we have tested the second hypothesis, and
show that it is consistent with the data obtained.
Unlike mammals and Drosophila, C. elegans has four ace-
tylcholinesterase genes [10,8]. ace-1 and ace-2 contribute ap-
proximately 95% of the total AChE activity. The ace-1 muta-
tion ace-1(p1000) is likely to be a null mutation because it is
caused by a premature stop codon leaving a predicted protein
of 98 instead of 620 amino acids [16]. The molecular nature of
ace-2(g72) and of ace-3(dc2) is unknown.
The fact that single mutants in each of these genes, ace-1-
(p1000) and ace-2(g72), have no behavioral phenotype sug-
gests that they functionally overlap. However, ace-1 is ex-
pressed mainly in muscle cells [12,13,17] whereas ace-2 is ex-
pressed mainly in neurons [18]. Once synthesized, both
enzymes are likely to be transported and anchored to synaptic
sites where both are able to hydrolyze acetylcholine. We spec-
ulate that these steps might be a¡ected by the lack of the dys-1
product. We then tested the signi¢cance of our in vitro results
by an in vivo assay.
3.2. Behavioral defects of ace-1 dys-1(cx26) and
ace-2 dys-1(cx26) double mutants
The rationale for this experiment was as follows: if dys-1
mutations reduce acetylcholinesterase activity in the animal,
then combining a dys-1 mutation with either the ace-1(p1000)
or the ace-2(g72) mutation may impair animal locomotion by
bringing acetylcholinesterases under a critical threshold.
Our results show that this is the case: whereas ace-1 and
ace-2 mutants locomote normally, ace-1 dys-1(cx26) and ace-
2 dys-1(cx26) double mutants are uncoordinated and hyper-
contracted in a way reminiscent of ace-1 ace-2 double mutants
(also similar to worms exposed to acetylcholinesterase inhib-
itors), but with a milder phenotype (Table 1). In particular,
the animals have di⁄culties moving backwards and often fail
to produce the appropriate locomotor response when prodded
either anteriorly or posteriorly. They instead hypercontract
Table 1
Behavioral phenotypes of dys-1 ace-1 and dys-1 ace-2 mutants
Genotype Locomotor activity Forward locomotion Backward locomotion Hypercontraction
N2 +++ +++ +++ 3
dys-1(cx26) ++++a +++ ++ +
ace-1(p1000) +++ +++ +++ 3
ace-2(g72) +++ +++ +++ 3
ace-1(p1000) ace-2(g72) 3 + 3 +++
dys-1(cx26) ace-1(p1000) + + + ++
dys-1(cx26) ace-2(g72) ++ ++ + +
Semi-quantitative description of the locomotor pattern of the animals. (wild-type is rated +++, excepted for column ’hypercontraction’ where
wild-type is rated 3). Locomotor activity describes the spontaneous activity of the animals. Forward and backward locomotion describe the
ability of the animals to produce wild-type-like sinusoidal tracks. Hypercontraction describes the tendency to hypercontract when prodded.
adys-1 animals are spontaneously hyperactive.
Fig. 1. Acetylcholinesterase-speci¢c activity in wild-type and mutant
backgrounds. Bars represent the mean AChE-speci¢c activity for
each genotype. Error bars indicate the S.E.M. Numbers above each
bar indicate the percentage of wild-type activity. Each bar represents
a minimum of eight measurements. Values were compared by a
paired Student’s t-test. Asterisks indicate statistically signi¢cant dif-
ferences to wild-type with P6 0.05. All three dys-1 alleles tested
showed reduced AChE activity.
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for a few seconds before relaxing. This behavioral defect is
common to most hypercontracting mutations in C. elegans.
Locomotor defects in C. elegans can be of many di¡erent
types. Strikingly, the ones exhibited by the double mutants
ace-1 dys-1 and ace-2 dys-1 resemble those of ace-1 ace-2
animals, as well as phenocopies obtained by exposing wild-
type animals to the AChE inhibitor aldicarb.
These results, as well as the reduction of AChE activity
found in ace-1 dys-1 and ace-2 dys-1 mutants, suggest that
the dys-1 mutation a¡ects both ace-1 and ace-2. The nature
of the interaction between ace genes and dys-1 remains to be
explained.
In the mouse model of Duchenne muscular dystrophy, the
mdx mouse, Oliver and coworkers have reported a modi¢ca-
tion of the distribution of AChE patches in muscles observed
by £uorescence microscopy [19]. Another notable e¡ect of the
mdx mutation is an elevated level of acetylcholinesterase in
the serum [19]. It is likely that this excess of AChE activity
originates from the muscles.
How can the mouse and C. elegans data be reconciled? One
common interpretation is to say that dystrophin absence leads
to local disorganizations of the muscle membrane. As a con-
sequence, acetylcholinesterase anchoring might be perturbed,
leading to elevated serum levels in mice and reduced total
activity in the worm. For example, some forms of AChE
bind to perlecan, which itself binds to K-dystroglycan, a com-
ponent of the dystrophin complex [20]. One could speculate
that the lack of dystrophin, known to perturb the dystrophin
complex, would in turn modify membrane and extracellular
matrix clues necessary for proper AChE attachment. Such a
local disorganization would also explain why other proteins,
like the neuronal nitric oxide synthase, are mislocalized in
mdx mice [21].
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